Nektar begins two phase III ZENITH AD studies of rezpeg for moderate-to-severe atopic dermatitis, wi

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Two global registrational Phase 3 trials initiated in ZENITH AD program Phase 3 program based upon c

SAN FRANCISCO, June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that

Robin sold 20,000 shares over two days for a transaction value of $1.22 million at a weighted averag

Big pharma's appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeu

SAN FRANCISCO, June 3, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that,

SAN FRANCISCO, May 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that

This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidat

Nektar Therapeutics NASDAQ: NKTR outlined plans to advance its lead regulatory T-cell (Treg) therapy

NKTR misses Q1 earnings and revenue estimates. Investor focus stays on rezpeg as the company advance

Nektar Therapeutics (NKTR) Q1 2026 Earnings Call Transcript

SAN FRANCISCO, May 7, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financi

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been f

New York, New York--(Newsfile Corp. - May 5, 2026) - WHY: Rosen Law Firm, a global investor rights l

NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has b

LOS ANGELES, May 05, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of

New York, New York--(Newsfile Corp. - May 5, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationa

NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recogniz

Nektar Therapeutics is significantly de-risked after positive Rezpeg phase 2 data in atopic dermatit

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff

Nektar Therapeutics (NASDAQ: NKTR) rose on positive results for alopecia treatment. Other top gainer

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for it

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn

  On Thursday, 241 companies hit new 52-week lows.

  Monday saw 196 companies set new 52-week lows.

  During Monday's trading, 1214 companies set new 52-week lows.

    On Friday, 209 companies set new 52-week lows.

  Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly e

Stocks That Hit 52-Week Lows On Monday

Stocks That Hit 52-Week Lows On Thursday